Alvotech, a global biotechnology company, secured a $100 million senior term loan facility with maturity in December 2027 aimed at strengthening liquidity and supporting the execution of Alvotech’s strategic priorities in 2026.
“This USD 100 million financing underscores the long-term commitment of our financing partners at GoldenTree and their alignment with Alvotech’s strategy,” Robert Wessman, chairman and CEO of Alvotech, said. “Their support strengthens our ability to execute on our growth plans, invest in R&D and deliver high-quality biosimilars to patients worldwide.”
The transaction was led by GoldenTree Asset Management. Alvotech remains committed to advancing its R&D pipeline.
The transaction, a senior term loan facility in an aggregate principal amount of $100 million, bears an interest rate of 12.50%, payable monthly in cash, and has a maturity date of two years. The transaction replaces the company’s previously disclosed working capital facility (ABL) and provides Alvotech with access to the full $100 million throughout the term of the loan. This structure offers enhanced operational flexibility.
